The arrows denote the position of the active fragment of HTRA-1 that contains the protease activity

The arrows denote the position of the active fragment of HTRA-1 that contains the protease activity. 88 kDa. In gel tryptic digestion and subsequent peptide analysis by LC-MS/MS showed that the band contained human complement 1s. A panel of protease inhibitors was tested for their ability to inhibit IGFBP-5 cleavage by the purified protease. Three serine protease inhibitors, FUT175 and CP 143217 and CB-349547 had IC50s between 1and 6 uM. Two other serine protease inhibitors had intermediate activity (e.g. IC50s 2040 uM) and MMP inhibitors had no detectible activity at concentrations up to 300 uM. == Conclusion == Human OA fluid contains a serine protease that cleaves IGFBP-5. Zymography, immunoblotting and LCMS/MS analysis indicate that complement 1s is the CID-2858522 protease that accounts for this activity. Keywords:Insulin-like growth factor I, Insulin-like growth factor binding protein-5, complement 1s, chondrocyte == Introduction == IGF-I is a potent stimulant of chrondrocyte extracellular matrix protein synthesis and growth(1,2). Following its synthesis in liver IGF-I is transported to target tissues, such as cartilage, where it stimulates growth (3). IGF-I is also synthesized by cartilage and this locally synthesized IGF-I stimulates epiphyseal growth (4). Direct injection of GH into the growth plate of hyposphysectomized animals stimulates IGF-I synthesis and cartilage growth. Simultaneous administration of an IGF-I antibody results in attenuation of the cartilage growth response (5). In mice deletion of hepatic IGF-I gene expression reduces blood IGF-I concentrations by 80% but has a minimal effect on statural growth (6% reduction) whereas if IGF-I synthesis in cartilage and other tissues is eliminated growth is attenuated by 50% (6,7). In addition, growth plate chondrocytes in the proliferative zone possess abundant IGF-I receptors and both growth plate and articular chondrocytes respond to IGF-I in vitro with increases CID-2858522 in DNA and proteoglycan synthesis (2,8). Together, these findings support the conclusion that locally produced IGF-I is an important cartilage growth factor. Treatment of canine osteoarthritis with IGF-I Rabbit Polyclonal to Cytochrome P450 4F3 results in articular cartilage preservation and exposure CID-2858522 to other cartilage growth factors enhances the cartilage response to IGF-I (9,10). In human osteoarthritis there is upregulation of IGF-I synthesis (11). There is also increased IGF-I synthesis in the synovium of inflamed joints and IGF-I augments chondrocyte proliferation after in vivo injury (12,13). Furthermore adenoviral mediated gene transfer of IGF-I into joints has been shown to have a protective function CID-2858522 for articular chondrocytes in animal models of arthritis (1417). IGF binding proteins are synthesized by articular cartilage both during normal growth and during repair after injury (12) (1820). Both IGFBP-3 and 5 have been shown to be upregulated during the early phases of articular chondrocyte differentiation and then downregulated when the cells become hypertrophic (18). Upregulation of IGFBP-5 was shown to be associated with enhanced IGF-I activation of the PI-3 kinase pathway in growth plate chondrocytes (21). In osteoarthritic articular cartilage, there is enhanced expression of IGFBP-3, 4 and 5 (20). The ratio between IGF-I and IGF binding proteins appears to be important since disruption of the IGFBP-3/IGF-I complex has been shown to enhance IGF-I actions (22), however IGFBPs also perform an important storage function in the joint and if all binding activity is eliminated IGF-I is a less effective growth stimulant. IGFBP-3 is abundant on the surface of articular chondrocytes and in osteoarthritic joints and has been reported to make the cells refractory to IGF-I (23). However in some studies IGFBP-5 enhanced both growth plate and articular chondrocyte proliferation (21,24,25). One variable that regulates IGFBP-5 is proteolysis and IGFBP-5 protease activity is increased in joint fluid during the development of arthritis (2427). Inhibition IGFBP-5 cleavage was shown to limit the amount of articular cartilage destruction in dogs during the development of osteoarthritis. This was associated with an increase in the amount of IGF-I in joint fluid as well as an increase in intact IGFBP-5 (24). These findings suggest that in certain situations IGFBP-5 can act as a reservoir for IGFs in cartilage CID-2858522 and synovial fluid and that factors that regulate rate of IGFBP-5 cleavage may alter the ability of this tissue to respond to IGF-I. Several proteases have been shown to cleave.